Media headlines about Humana (NYSE:HUM) have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Humana earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news headlines about the insurance provider an impact score of 45.4933300113836 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:

Humana (HUM) traded up 1.89% during mid-day trading on Wednesday, reaching $254.96. 1,353,904 shares of the company’s stock traded hands. The stock has a 50 day moving average of $237.33 and a 200 day moving average of $221.21. The company has a market cap of $36.85 billion, a P/E ratio of 20.97 and a beta of 0.91. Humana has a 12-month low of $163.50 and a 12-month high of $255.10.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.08 by $0.41. The business had revenue of $13.53 billion during the quarter, compared to analyst estimates of $13.61 billion. Humana had a net margin of 3.37% and a return on equity of 15.85%. During the same period in the prior year, the business posted $2.30 earnings per share. On average, equities research analysts predict that Humana will post $11.45 earnings per share for the current fiscal year.

HUM has been the subject of several analyst reports. Zacks Investment Research upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $237.00 price objective for the company in a research note on Tuesday, April 18th. Jefferies Group LLC downgraded shares of Humana from a “buy” rating to a “hold” rating and reduced their target price for the company from $237.00 to $221.00 in a research report on Friday, April 21st. Cowen and Company reissued an “outperform” rating and set a $230.00 target price on shares of Humana in a research report on Tuesday, April 25th. Evercore ISI reissued an “outperform” rating and set a $240.00 target price on shares of Humana in a research report on Tuesday, April 25th. Finally, Cantor Fitzgerald increased their target price on shares of Humana from $190.00 to $200.00 and gave the company a “neutral” rating in a research report on Wednesday, April 26th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $243.65.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-humana-hum-stock-price/1466790.html.

In other Humana news, SVP Brian P. Leclaire sold 4,971 shares of the company’s stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total value of $1,193,040.00. Following the completion of the transaction, the senior vice president now directly owns 14,258 shares in the company, valued at $3,421,920. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Heidi S. Margulis sold 1,500 shares of the company’s stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $231.96, for a total transaction of $347,940.00. Following the completion of the transaction, the vice president now owns 8,150 shares of the company’s stock, valued at $1,890,474. The disclosure for this sale can be found here. Corporate insiders own 0.80% of the company’s stock.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Insider Buying and Selling by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.